HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CUTIA-B

1.910

-0.045-2.30%

Volume:69.40K

Turnover:133.41K

Market Cap:712.43M

PE:-1.85

High:1.970

Open:1.910

Low:1.880

Close:1.955

52wk High:11.670

52wk Low:1.830

Shares:373.00M

HK Float Shares:373.00M

Volume Ratio:0.45

T/O Rate:0.02%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.030

ROE:-36.58%

ROA:-14.29%

PB:0.69

PE(LYR):-1.85

PS:1.82

Loading ...

Overview Company News Filings

Cutia Therapeutics Updates Cayman Registrar Name to Ascentium (Cayman) Limited

Bulletin Express

Cutia Therapeutics 2025年度简讯：收入同比增20.2%至3.362亿人民币，核心皮肤科产品商业化显著提升业绩

Bulletin Express

Cutia Posts RMB336.20 Million Revenue; ESG Drive Cuts Carbon Intensity 16.67 %

Bulletin Express

CUTIA-B schedules 26 Jun 2026 AGM to approve board renewals, 10% buyback and 20% issuance mandates

Bulletin Express

Cutia Therapeutics announces annual general meeting

Cutia Therapeutics publishes 2025 annual report

CUTIA-B Shares Climb Over 3% Following Completion of Phase III Trial for Injectable Botulinum Toxin

Cutia Therapeutics completes China Phase III trial of CU-20101 for glabellar lines

Cutia Therapeutics Completes Phase 3 Trial for Botulinum Toxin Product

MT Newswires Live

BRIEF-Cutia Therapeutics Says Completion Of Phase III Clinical Trial Of Cu-20101

CUTIA-B Completes Phase III Trial in China for Botulinum Toxin Type A Injection Targeting Glabellar Lines

Cutia Therapeutics - Completion of Phase Iii Clinical Trial of Cu-20101

THOMSON REUTERS

Cutia Therapeutics Reports Stable Share Capital in March; Confirms Public-Float Compliance

Bulletin Express

Cutia Therapeutics (SEHK:2487) Margins Stay Deep In The Red Challenging Profitability Narrative

Simply Wall St.

CUTIA-B Reports Annual Results: Shareholder Loss Narrows by 21.58% to RMB 340 Million

Cutia Therapeutics launches CU-40102 and CU-10201, reporting CNY 336 million in 2025 revenue

Cutia Therapeutics FY2025 loss narrows 21.6% to RMB340 million on revenue up 20.2% to RMB336 million

Cutia Therapeutics - FY Revenue RMB336 Mln

THOMSON REUTERS

Fidelity International Increases Stake in CUTIA-B by 1.79 Million Shares at HK$5.01 Each

CUTIA-B Secures Implied Clinical Trial Approval from China's NMPA for Topical Dutasteride Formulation

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/02487/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02487","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02487\",,,,,undefined,":{"symbol":"02487","market":"HK","secType":"STK","nameCN":"CUTIA-B","latestPrice":1.91,"timestamp":1788163500230,"preClose":1.955,"halted":0,"volume":69400,"delay":0,"changeRate":-0.02301790281329931,"floatShares":373000000,"shares":373000000,"eps":-1.03,"marketStatus":"Not Yet Opened","change":-0.045,"latestTime":"08-31 16:05:00","open":1.91,"high":1.97,"low":1.88,"amount":133407,"amplitude":0.046036,"askPrice":1.93,"askSize":2000,"bidPrice":1.88,"bidSize":12800,"shortable":0,"etf":0,"ttmEps":-1.009,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":0,"adr":0,"listingDate":1686499200000,"exchange":"SEHK","adjPreClose":1.955,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"volumeRatio":0.44578622793125067,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02487\",,,,,undefined,":{"symbol":"02487","floatShares":373000000,"roa":"-14.29%","roe":"-36.58%","lyrEps":-1.03,"volumeRatio":0.44578622793125067,"shares":373000000,"dividePrice":0,"high":1.97,"amplitude":0.046036,"preClose":1.955,"low":1.88,"week52Low":1.83,"pbRate":"0.69","psRate":"1.82","week52High":11.67,"institutionHeld":0,"latestPrice":1.91,"committee":0.72973,"eps":-1.03,"divideRate":0,"volume":69400,"delay":0,"ttmEps":-1.009,"open":1.91,"prevYearClose":4.54,"prevWeekClose":1.955,"prevMonthClose":1.91,"prevQuarterClose":2.83,"fiveDayClose":1.87,"twentyDayClose":2.59,"sixtyDayClose":3.43},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02487\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"02487","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null},{"market":"HK","date":"2026-03-24","symbol":"02487","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774281600000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-28","symbol":"02487","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756344600000,"name":null,"time":"","dateTimestamp":1756310400000,"actualEps":null},{"date":"2025-03-24","symbol":"02487","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"Post-Mkt","dateTimestamp":1742745600000,"actualEps":null},{"market":"HK","date":"2024-08-29","symbol":"02487","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1724860800000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02487\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02487\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1775145600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02487\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02487","date":"2026-08-31","current":-1.892963,"percent":0.782828,"low":-15.485925,"twenty":-6.129859,"median":-3.380772,"eighty":-1.407215,"high":-0.826569,"avg":-4.086924,"sd":2.791511,"marketCap":694033409},"quantilePoints":[{"date":"2023-06-16","current":-15.411162,"twenty":-14.413676,"median":-12.389874,"eighty":-12.075055,"marketCap":9394355968},{"date":"2023-06-23","current":-12.436662,"twenty":-14.898766,"median":-13.544522,"eighty":-12.376412,"marketCap":7539806732},{"date":"2023-06-30","current":-12.398371,"twenty":-14.32145,"median":-12.394122,"eighty":-11.447458,"marketCap":7448599392},{"date":"2023-07-07","current":-11.154992,"twenty":-13.792435,"median":-12.336647,"eighty":-11.411148,"marketCap":6688538230},{"date":"2023-07-14","current":-10.800615,"twenty":-12.879806,"median":-11.67313,"eighty":-11.073156,"marketCap":6566928444},{"date":"2023-07-21","current":-9.796084,"twenty":-12.413687,"median":-11.417592,"eighty":-10.790615,"marketCap":5928477067},{"date":"2023-07-28","current":-10.460353,"twenty":-12.393273,"median":-11.232297,"eighty":-10.42688,"marketCap":6323708872},{"date":"2023-08-04","current":-10.844647,"twenty":-12.36968,"median":-11.144468,"eighty":-10.471016,"marketCap":6566928444},{"date":"2023-08-11","current":-11.613111,"twenty":-12.376412,"median":-11.154992,"eighty":-10.495819,"marketCap":6992562695},{"date":"2023-08-18","current":-11.061159,"twenty":-12.34839,"median":-11.14973,"eighty":-10.533878,"marketCap":6612532113},{"date":"2023-08-25","current":-12.606042,"twenty":-12.421346,"median":-11.281516,"eighty":-10.611978,"marketCap":7539806732},{"date":"2023-09-01","current":-3.762061,"twenty":-12.421346,"median":-11.154992,"eighty":-10.467461,"marketCap":7904636090},{"date":"2023-09-08","current":-3.045502,"twenty":-12.394972,"median":-11.061159,"eighty":-10.227752,"marketCap":6323708872},{"date":"2023-09-15","current":-3.276331,"twenty":-12.381613,"median":-10.935179,"eighty":-6.512762,"marketCap":6855751685},{"date":"2023-09-22","current":-3.006155,"twenty":-12.36402,"median":-10.844647,"eighty":-3.792803,"marketCap":6262903979},{"date":"2023-09-29","current":-2.913601,"twenty":-12.34839,"median":-10.788114,"eighty":-3.305013,"marketCap":6080489300},{"date":"2023-10-06","current":-3.060747,"twenty":-12.287596,"median":-10.741943,"eighty":-3.213384,"marketCap":6384513765},{"date":"2023-10-13","current":-3.036132,"twenty":-12.066426,"median":-10.551151,"eighty":-3.148051,"marketCap":6323708872},{"date":"2023-10-20","current":-3.106604,"twenty":-11.932534,"median":-10.469238,"eighty":-3.120451,"marketCap":6460519881},{"date":"2023-10-27","current":-2.925118,"twenty":-11.796455,"median":-10.343076,"eighty":-3.068613,"marketCap":6080489300},{"date":"2023-11-03","current":-2.990305,"twenty":-11.691357,"median":-10.218458,"eighty":-3.045502,"marketCap":6232501532},{"date":"2023-11-10","current":-3.268138,"twenty":-11.654904,"median":-9.796084,"eighty":-3.060747,"marketCap":6810148016},{"date":"2023-11-17","current":-3.108791,"twenty":-11.613111,"median":-4.217909,"eighty":-3.060747,"marketCap":6536525997},{"date":"2023-11-24","current":-2.853944,"twenty":-11.467369,"median":-3.800488,"eighty":-3.019641,"marketCap":6050086853},{"date":"2023-12-01","current":-2.756466,"twenty":-11.417592,"median":-3.514265,"eighty":-2.990305,"marketCap":5867672174},{"date":"2023-12-08","current":-2.351787,"twenty":-11.401481,"median":-3.313885,"eighty":-2.93822,"marketCap":4986001226},{"date":"2023-12-15","current":-1.83926,"twenty":-11.309603,"median":-3.276331,"eighty":-2.913601,"marketCap":3921915598},{"date":"2023-12-22","current":-1.398202,"twenty":-11.281516,"median":-3.266894,"eighty":-2.872719,"marketCap":2979439757},{"date":"2023-12-29","current":-1.558248,"twenty":-11.205602,"median":-3.218707,"eighty":-2.860632,"marketCap":3338188625},{"date":"2024-01-05","current":-1.057644,"twenty":-11.154992,"median":-3.21182,"eighty":-2.802771,"marketCap":2249781041},{"date":"2024-01-12","current":-0.999942,"twenty":-11.150782,"median":-3.160184,"eighty":-2.759084,"marketCap":2128171255},{"date":"2024-01-19","current":-0.956974,"twenty":-11.111144,"median":-3.130992,"eighty":-2.490877,"marketCap":2033923670},{"date":"2024-01-26","current":-1.01241,"twenty":-11.026152,"median":-3.120712,"eighty":-2.309623,"marketCap":2143372478},{"date":"2024-02-02","current":-0.936815,"twenty":-10.964346,"median":-3.106604,"eighty":-1.836456,"marketCap":1980801062},{"date":"2024-02-09","current":-0.896369,"twenty":-10.938224,"median":-3.073227,"eighty":-1.544488,"marketCap":1904616406},{"date":"2024-02-16","current":-0.959266,"twenty":-10.919956,"median":-3.067843,"eighty":-1.412953,"marketCap":2038701401},{"date":"2024-02-23","current":-0.899483,"twenty":-10.863612,"median":-3.062215,"eighty":-1.31118,"marketCap":1901569020},{"date":"2024-03-01","current":-1.152465,"twenty":-10.844647,"median":-3.040182,"eighty":-1.17923,"marketCap":2437909000},{"date":"2024-03-08","current":-0.971959,"twenty":-10.843385,"median":-3.012898,"eighty":-1.152465,"marketCap":2056985718},{"date":"2024-03-15","current":-1.145767,"twenty":-10.800615,"median":-3.003359,"eighty":-1.102403,"marketCap":2422672068},{"date":"2024-03-22","current":-1.210287,"twenty":-10.775614,"median":-2.971683,"eighty":-1.108733,"marketCap":2556757063},{"date":"2024-03-28","current":-1.130651,"twenty":-10.768565,"median":-2.94471,"eighty":-1.126268,"marketCap":2404387751},{"date":"2024-04-05","current":-1.018114,"twenty":-10.746915,"median":-2.925118,"eighty":-1.078437,"marketCap":2163644237},{"date":"2024-04-12","current":-1.011803,"twenty":-10.711537,"median":-2.916466,"eighty":-1.052694,"marketCap":2151454692},{"date":"2024-04-19","current":-0.965334,"twenty":-10.642392,"median":-2.906537,"eighty":-1.046989,"marketCap":2050890946},{"date":"2024-04-26","current":-1.03546,"twenty":-10.539635,"median":-2.868164,"eighty":-1.036496,"marketCap":2197165486},{"date":"2024-05-03","current":-1.095099,"twenty":-10.513514,"median":-2.860037,"eighty":-1.038246,"marketCap":2322108322},{"date":"2024-05-10","current":-1.015083,"twenty":-10.47457,"median":-2.807837,"eighty":-1.032578,"marketCap":2157549465},{"date":"2024-05-17","current":-1.060526,"twenty":-10.460353,"median":-2.785798,"eighty":-1.029219,"marketCap":2239828893},{"date":"2024-05-24","current":-1.149726,"twenty":-10.37667,"median":-2.759739,"eighty":-1.030854,"marketCap":2422672068},{"date":"2024-05-31","current":-1.040202,"twenty":-10.309482,"median":-2.716272,"eighty":-1.030854,"marketCap":2194118100},{"date":"2024-06-07","current":-0.954703,"twenty":-10.241692,"median":-2.483148,"eighty":-1.020882,"marketCap":2011274925},{"date":"2024-06-14","current":-0.88753,"twenty":-10.223105,"median":-2.348826,"eighty":-1.015017,"marketCap":1868047771},{"date":"2024-06-21","current":-0.879235,"twenty":-9.893357,"median":-2.097181,"eighty":-1.011704,"marketCap":1846716067},{"date":"2024-06-28","current":-0.930402,"twenty":-9.799284,"median":-1.836923,"eighty":-1.004715,"marketCap":1953374586},{"date":"2024-07-05","current":-0.911731,"twenty":-9.796084,"median":-1.670031,"eighty":-0.989934,"marketCap":1913758565},{"date":"2024-07-12","current":-0.998824,"twenty":-6.512762,"median":-1.535315,"eighty":-0.975822,"marketCap":2099649126},{"date":"2024-07-19","current":-1.078316,"twenty":-4.260297,"median":-1.440488,"eighty":-0.983109,"marketCap":2266795296},{"date":"2024-07-26","current":-1.109957,"twenty":-4.076914,"median":-1.398202,"eighty":-0.988979,"marketCap":2341976752},{"date":"2024-08-02","current":-1.019736,"twenty":-3.896516,"median":-1.341466,"eighty":-0.989934,"marketCap":2150360472},{"date":"2024-08-09","current":-1.088923,"twenty":-3.792803,"median":-1.273961,"eighty":-0.992426,"marketCap":2311561470},{"date":"2024-08-16","current":-1.21024,"twenty":-3.761985,"median":-1.221942,"eighty":-0.996911,"marketCap":2570091371},{"date":"2024-08-23","current":-1.4747,"twenty":-3.613333,"median":-1.260835,"eighty":-0.999495,"marketCap":3144940210},{"date":"2024-08-30","current":-6.768747,"twenty":-3.613333,"median":-1.282548,"eighty":-1.003043,"marketCap":3899239216},{"date":"2024-09-06","current":-6.86048,"twenty":-4.076914,"median":-1.344748,"eighty":-1.005589,"marketCap":3953986725},{"date":"2024-09-13","current":-7.629828,"twenty":-6.773268,"median":-1.399159,"eighty":-1.006459,"marketCap":4385883736},{"date":"2024-09-20","current":-7.679018,"twenty":-6.86048,"median":-1.408171,"eighty":-1.008176,"marketCap":4440631245},{"date":"2024-09-27","current":-8.467696,"twenty":-7.210357,"median":-1.4747,"eighty":-1.010386,"marketCap":4926157965},{"date":"2024-10-04","current":-8.045497,"twenty":-7.438254,"median":-1.528968,"eighty":-1.010794,"marketCap":4659279943},{"date":"2024-10-10","current":-6.916807,"twenty":-7.445917,"median":-1.535454,"eighty":-1.011308,"marketCap":3979699659},{"date":"2024-10-18","current":-6.535297,"twenty":-7.4076,"median":-1.599022,"eighty":-1.011803,"marketCap":3740585295},{"date":"2024-10-25","current":-6.87674,"twenty":-7.395,"median":-1.716627,"eighty":-1.011971,"marketCap":3935766258},{"date":"2024-11-01","current":-6.487355,"twenty":-7.390607,"median":-1.836923,"eighty":-1.01241,"marketCap":3715412316},{"date":"2024-11-08","current":-5.268552,"twenty":-7.067714,"median":-2.097181,"eighty":-1.012524,"marketCap":2994521565},{"date":"2024-11-15","current":-4.934518,"twenty":-6.939983,"median":-2.348826,"eighty":-1.014752,"marketCap":2783467441},{"date":"2024-11-22","current":-4.525008,"twenty":-6.921031,"median":-2.487824,"eighty":-1.015083,"marketCap":2551002028},{"date":"2024-11-29","current":-4.212716,"twenty":-6.916807,"median":-2.719501,"eighty":-1.015704,"marketCap":2373594213},{"date":"2024-12-06","current":-4.301808,"twenty":-6.905598,"median":-2.763011,"eighty":-1.018114,"marketCap":2418082775},{"date":"2024-12-13","current":-4.02776,"twenty":-6.88455,"median":-2.792596,"eighty":-1.019736,"marketCap":2261974665},{"date":"2024-12-20","current":-3.895979,"twenty":-6.880216,"median":-2.853944,"eighty":-1.020882,"marketCap":2175955910},{"date":"2024-12-27","current":-3.693493,"twenty":-6.879252,"median":-2.860037,"eighty":-1.021555,"marketCap":2061264237},{"date":"2025-01-03","current":-3.393321,"twenty":-6.877861,"median":-2.868164,"eighty":-1.023476,"marketCap":1895598486},{"date":"2025-01-10","current":-2.994045,"twenty":-6.870236,"median":-2.906537,"eighty":-1.026058,"marketCap":1666215140},{"date":"2025-01-17","current":-2.591221,"twenty":-6.86048,"median":-2.868164,"eighty":-1.027008,"marketCap":1443203553},{"date":"2025-01-24","current":-2.296545,"twenty":-6.833199,"median":-2.860899,"eighty":-1.028243,"marketCap":1287095443},{"date":"2025-01-28","current":-2.466671,"twenty":-6.805918,"median":-2.857066,"eighty":-1.028894,"marketCap":1389043597},{"date":"2025-02-07","current":-2.798033,"twenty":-6.785996,"median":-2.820002,"eighty":-1.030527,"marketCap":1567452866},{"date":"2025-02-14","current":-3.403301,"twenty":-6.780924,"median":-2.832166,"eighty":-1.031664,"marketCap":1901970246},{"date":"2025-02-21","current":-2.965189,"twenty":-6.771007,"median":-2.858982,"eighty":-1.034711,"marketCap":1666215140},{"date":"2025-02-28","current":-3.128579,"twenty":-6.737748,"median":-2.857066,"eighty":-1.035452,"marketCap":1752233895},{"date":"2025-03-07","current":-3.795937,"twenty":-6.685693,"median":-2.863309,"eighty":-1.035834,"marketCap":2134539472},{"date":"2025-03-14","current":-3.17157,"twenty":-6.632156,"median":-2.878989,"eighty":-1.03679,"marketCap":1784092693},{"date":"2025-03-21","current":-3.342788,"twenty":-6.586773,"median":-2.907899,"eighty":-1.03784,"marketCap":1879669087},{"date":"2025-03-28","current":-4.261325,"twenty":-6.543854,"median":-2.91933,"eighty":-1.038839,"marketCap":1978431362},{"date":"2025-04-03","current":-3.930581,"twenty":-6.51804,"median":-2.925118,"eighty":-1.039278,"marketCap":1825509131},{"date":"2025-04-11","current":-3.073189,"twenty":-6.495027,"median":-2.922242,"eighty":-1.03967,"marketCap":1414530635},{"date":"2025-04-17","current":-3.165897,"twenty":-6.47136,"median":-2.94471,"eighty":-1.039975,"marketCap":1459132952},{"date":"2025-04-25","current":-3.918674,"twenty":-6.44197,"median":-2.955046,"eighty":-1.041501,"marketCap":1809579732},{"date":"2025-05-02","current":-4.151319,"twenty":-6.420376,"median":-2.965975,"eighty":-1.046698,"marketCap":1921085525},{"date":"2025-05-09","current":-4.238599,"twenty":-6.416374,"median":-2.989735,"eighty":-1.04728,"marketCap":1975245482},{"date":"2025-05-16","current":-4.366995,"twenty":-6.405055,"median":-3.003359,"eighty":-1.048429,"marketCap":2051706597},{"date":"2025-05-23","current":-5.848115,"twenty":-6.313401,"median":-3.007935,"eighty":-1.050731,"marketCap":2755786035},{"date":"2025-05-30","current":-6.515833,"twenty":-6.416374,"median":-3.036132,"eighty":-1.051354,"marketCap":3083931656},{"date":"2025-06-06","current":-6.996095,"twenty":-6.508395,"median":-3.039313,"eighty":-1.052,"marketCap":3319686762},{"date":"2025-06-13","current":-8.228236,"twenty":-6.545559,"median":-3.060747,"eighty":-1.052348,"marketCap":3905888647},{"date":"2025-06-20","current":-6.374949,"twenty":-6.632156,"median":-3.067399,"eighty":-1.052744,"marketCap":3020214059},{"date":"2025-06-27","current":-6.3035,"twenty":-6.639184,"median":-3.073189,"eighty":-1.053079,"marketCap":2994727021},{"date":"2025-07-04","current":-5.954515,"twenty":-6.641618,"median":-3.086246,"eighty":-1.054062,"marketCap":2829061271},{"date":"2025-07-11","current":-5.819562,"twenty":-6.627625,"median":-3.114534,"eighty":-1.055579,"marketCap":2762157795},{"date":"2025-07-18","current":-6.720769,"twenty":-6.641618,"median":-3.123457,"eighty":-1.057059,"marketCap":3187401188},{"date":"2025-07-25","current":-6.141724,"twenty":-6.627625,"median":-3.129786,"eighty":-1.059373,"marketCap":2923374942},{"date":"2025-08-01","current":-5.729361,"twenty":-6.595465,"median":-3.139962,"eighty":-1.061686,"marketCap":2710245321},{"date":"2025-08-08","current":-5.735189,"twenty":-6.557071,"median":-3.15919,"eighty":-1.06292,"marketCap":2719788439},{"date":"2025-08-15","current":-6.274508,"twenty":-6.540468,"median":-3.165897,"eighty":-1.063408,"marketCap":2971090528},{"date":"2025-08-22","current":-6.442504,"twenty":-6.540468,"median":-3.175987,"eighty":-1.065225,"marketCap":3041073389},{"date":"2025-08-29","current":-7.115719,"twenty":-6.557071,"median":-3.21131,"eighty":-1.067861,"marketCap":3674100172},{"date":"2025-09-05","current":-7.091352,"twenty":-6.584214,"median":-3.213297,"eighty":-1.074535,"marketCap":3657890365},{"date":"2025-09-12","current":-6.910072,"twenty":-6.659199,"median":-3.2277,"eighty":-1.082356,"marketCap":3570797737},{"date":"2025-09-19","current":-6.382019,"twenty":-6.693078,"median":-3.259314,"eighty":-1.087373,"marketCap":3295585034},{"date":"2025-09-26","current":-5.904859,"twenty":-6.659199,"median":-3.275781,"eighty":-1.091631,"marketCap":3041274561},{"date":"2025-10-03","current":-6.01226,"twenty":-6.644052,"median":-3.290255,"eighty":-1.094101,"marketCap":3103981253},{"date":"2025-10-10","current":-5.838578,"twenty":-6.633708,"median":-3.310057,"eighty":-1.095198,"marketCap":3009921215},{"date":"2025-10-17","current":-5.559086,"twenty":-6.615916,"median":-3.325304,"eighty":-1.096113,"marketCap":2863605600},{"date":"2025-10-24","current":-5.333971,"twenty":-6.590347,"median":-3.359906,"eighty":-1.098444,"marketCap":2748643331},{"date":"2025-10-31","current":-5.083015,"twenty":-6.578081,"median":-3.393321,"eighty":-1.099475,"marketCap":2623229947},{"date":"2025-11-07","current":-4.181079,"twenty":-6.543931,"median":-3.413605,"eighty":-1.102403,"marketCap":2156413463},{"date":"2025-11-14","current":-4.822607,"twenty":-6.543065,"median":-3.495515,"eighty":-1.108733,"marketCap":2494332858},{"date":"2025-11-21","current":-4.392956,"twenty":-6.538737,"median":-3.605298,"eighty":-1.109957,"marketCap":2271051731},{"date":"2025-11-28","current":-4.594159,"twenty":-6.537428,"median":-3.670872,"eighty":-1.109957,"marketCap":2383695897},{"date":"2025-12-05","current":-4.264675,"twenty":-6.535297,"median":-3.715228,"eighty":-1.111553,"marketCap":2216546489},{"date":"2025-12-12","current":-4.110256,"twenty":-6.53384,"median":-3.762061,"eighty":-1.113705,"marketCap":2140239151},{"date":"2025-12-19","current":-3.613255,"twenty":-6.530763,"median":-3.749448,"eighty":-1.113705,"marketCap":1885881357},{"date":"2025-12-24","current":-3.608975,"twenty":-6.526072,"median":-3.693493,"eighty":-1.114207,"marketCap":1889515040},{"date":"2026-01-02","current":-3.173126,"twenty":-6.5201,"median":-3.677848,"eighty":-1.115526,"marketCap":1667860391},{"date":"2026-01-09","current":-3.585899,"twenty":-6.512114,"median":-3.657564,"eighty":-1.121582,"marketCap":1889515040},{"date":"2026-01-16","current":-3.285591,"twenty":-6.502385,"median":-3.621768,"eighty":-1.129331,"marketCap":1736900364},{"date":"2026-01-23","current":-3.268106,"twenty":-6.492637,"median":-3.611115,"eighty":-1.133662,"marketCap":1725999315},{"date":"2026-01-30","current":-3.301176,"twenty":-6.480864,"median":-3.592259,"eighty":-1.140204,"marketCap":1751435095},{"date":"2026-02-06","current":-3.620741,"twenty":-6.465168,"median":-3.583052,"eighty":-1.144251,"marketCap":1925851868},{"date":"2026-02-13","current":-3.498174,"twenty":-6.452683,"median":-3.572107,"eighty":-1.147341,"marketCap":1871346626},{"date":"2026-02-20","current":-3.469208,"twenty":-6.44914,"median":-3.529701,"eighty":-1.148914,"marketCap":1853178212},{"date":"2026-02-27","current":-3.108602,"twenty":-6.443477,"median":-3.500418,"eighty":-1.149721,"marketCap":1678761439},{"date":"2026-03-06","current":-3.188132,"twenty":-6.431634,"median":-3.482285,"eighty":-1.150014,"marketCap":1707830901},{"date":"2026-03-13","current":-3.37608,"twenty":-6.424297,"median":-3.46792,"eighty":-1.151989,"marketCap":1816841385},{"date":"2026-03-20","current":-3.050022,"twenty":-6.420929,"median":-3.449202,"eighty":-1.157177,"marketCap":1635157246},{"date":"2026-03-27","current":-4.490263,"twenty":-6.416374,"median":-3.449778,"eighty":-1.164557,"marketCap":1729632998},{"date":"2026-04-02","current":-4.34674,"twenty":-6.411798,"median":-3.46792,"eighty":-1.170777,"marketCap":1682395122},{"date":"2026-04-10","current":-4.294839,"twenty":-6.408569,"median":-3.475043,"eighty":-1.174833,"marketCap":1675127756},{"date":"2026-04-17","current":-4.42341,"twenty":-6.404645,"median":-3.496844,"eighty":-1.178732,"marketCap":1725999315},{"date":"2026-04-24","current":-4.413848,"twenty":-6.398384,"median":-3.514265,"eighty":-1.179711,"marketCap":1722365632},{"date":"2026-04-30","current":-4.282382,"twenty":-6.382019,"median":-3.572107,"eighty":-1.181633,"marketCap":1671494074},{"date":"2026-05-08","current":-4.249016,"twenty":-6.374949,"median":-3.589079,"eighty":-1.198373,"marketCap":1664226708},{"date":"2026-05-15","current":-4.052809,"twenty":-6.34837,"median":-3.608975,"eighty":-1.21024,"marketCap":1591553053},{"date":"2026-05-22","current":-3.858061,"twenty":-6.318006,"median":-3.618969,"eighty":-1.210287,"marketCap":1511612032},{"date":"2026-05-29","current":-3.317895,"twenty":-6.306401,"median":-3.615796,"eighty":-1.214673,"marketCap":1304492114},{"date":"2026-06-05","current":-3.303858,"twenty":-6.293606,"median":-3.592369,"eighty":-1.225646,"marketCap":1300858431},{"date":"2026-06-12","current":-2.973638,"twenty":-6.288695,"median":-3.583052,"eighty":-1.242193,"marketCap":1170045851},{"date":"2026-06-18","current":-2.948095,"twenty":-6.279939,"median":-3.550904,"eighty":-1.254786,"marketCap":1162778486},{"date":"2026-06-26","current":-2.499662,"twenty":-6.270524,"median":-3.502662,"eighty":-1.268711,"marketCap":981094347},{"date":"2026-07-03","current":-2.534798,"twenty":-6.254076,"median":-3.495515,"eighty":-1.27574,"marketCap":995629078},{"date":"2026-07-10","current":-2.454551,"twenty":-6.23066,"median":-3.472125,"eighty":-1.281721,"marketCap":962925934},{"date":"2026-07-17","current":-2.242795,"twenty":-6.221134,"median":-3.450354,"eighty":-1.296485,"marketCap":882984913},{"date":"2026-07-24","current":-2.223836,"twenty":-6.201146,"median":-3.436238,"eighty":-1.324607,"marketCap":875717547},{"date":"2026-07-31","current":-2.155149,"twenty":-6.18189,"median":-3.419231,"eighty":-1.350149,"marketCap":850281768},{"date":"2026-08-07","current":-2.325624,"twenty":-6.175555,"median":-3.403301,"eighty":-1.377042,"marketCap":919321740},{"date":"2026-08-14","current":-2.047266,"twenty":-6.16769,"median":-3.397557,"eighty":-1.398585,"marketCap":810311257},{"date":"2026-08-21","current":-1.786263,"twenty":-6.139816,"median":-3.393321,"eighty":-1.400771,"marketCap":708568140},{"date":"2026-08-28","current":-1.790437,"twenty":-6.131021,"median":-3.380823,"eighty":-1.405303,"marketCap":710384981},{"date":"2026-08-31","current":-1.74997,"twenty":-6.129859,"median":-3.380772,"eighty":-1.407215,"marketCap":694033409}],"updateTime":1788219287381},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02487\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1153511949","title":"Cutia Therapeutics Updates Cayman Registrar Name to Ascentium (Cayman) Limited","url":"https://stock-news.laohu8.com/highlight/detail?id=1153511949","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153511949?lang=en_us&edition=fundamental","pubTime":"2026-04-27 21:03","pubTimestamp":1777295031,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics announced that, effective 17 April 2026, the name of its principal share registrar, transfer office and registered office in the Cayman Islands has been changed from Harneys...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104183992","title":"Cutia Therapeutics 2025年度简讯：收入同比增20.2%至3.362亿人民币，核心皮肤科产品商业化显著提升业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1104183992","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104183992?lang=en_us&edition=fundamental","pubTime":"2026-04-24 16:54","pubTimestamp":1777020895,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics于2025年度实现收入人民币3.362亿（上年同期为2.796亿），同比增长20.2%。公司重点推出的两款皮肤科核心产品——CU-40102（外用非那雄胺喷雾）与CU-10201（外用4%米诺环素气泡沫剂）于2025年10月底在中国获批并上市，为整体收入带来主要增量。同时，头皮护理和皮肤护理等既有业务保持稳定需求，进一步支撑销售。...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cutia Therapeutics 2025年度简讯：收入同比增20.2%至3.362亿人民币，核心皮肤科产品商业化显著提升业绩","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171173533","title":"Cutia Posts RMB336.20 Million Revenue; ESG Drive Cuts Carbon Intensity 16.67 %","url":"https://stock-news.laohu8.com/highlight/detail?id=1171173533","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171173533?lang=en_us&edition=fundamental","pubTime":"2026-04-24 16:45","pubTimestamp":1777020339,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics (CUTIA-B) released its 2025 Environmental, Social & Governance Report, highlighting a year of commercial milestones and measurable sustainability gains. Financial and Commercial...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198997593","title":"CUTIA-B schedules 26 Jun 2026 AGM to approve board renewals, 10% buyback and 20% issuance mandates","url":"https://stock-news.laohu8.com/highlight/detail?id=1198997593","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198997593?lang=en_us&edition=fundamental","pubTime":"2026-04-24 16:45","pubTimestamp":1777020303,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics (CUTIA-B) has issued a circular convening its Annual General Meeting for 10:00 a.m. on 26 June 2026 at its Shanghai headquarters. Key resolutions: 1. Board composition   • Five...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629857819","title":"Cutia Therapeutics announces annual general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629857819","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629857819?lang=en_us&edition=fundamental","pubTime":"2026-04-24 16:39","pubTimestamp":1777019977,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics will hold its annual general meeting in Shanghai on June 26, 2026.Shareholders will receive audited consolidated financial statements and directors’ and auditors’ reports for fiscal 2025.Votes will be held on re-election of board members, including non-executive and independent non-executive directors.Resolution will seek authority for directors to set directors’ remuneration.Proposals include re-appointing Ernst & Young as auditor, share repurchase mandate up to 10%, share issuance mandate up to 20%, and an extension of issuance capacity linked to any shares repurchased.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cutia Therapeutics published the original content used to generate this news brief via IIS, the Issu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL7w9HXX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629481613","title":"Cutia Therapeutics publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2629481613","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629481613?lang=en_us&edition=fundamental","pubTime":"2026-04-24 16:31","pubTimestamp":1777019504,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics released its 2025 annual report, highlighting rapid ramp-up in commercialization of key dermatology products.Topical finasteride spray CU-40102 secured China marketing clearance in June 2025, gained Hong Kong clearance in August 2025.Topical minocycline foam CU-10201, cleared in China in November 2024, began broader commercial rollout in late October 2025 alongside CU-40102.Localized adipose candidate CU-20401 posted positive Phase II results in China, setting up move toward Phase III.Management outlook flagged planned expansion of CU-10201, CU-40102 sales channels in 2026, with CU-30101 topical anesthetic positioned for potential China launch.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cutia Therapeutics publish","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL6B9nF7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139617375","title":"CUTIA-B Shares Climb Over 3% Following Completion of Phase III Trial for Injectable Botulinum Toxin","url":"https://stock-news.laohu8.com/highlight/detail?id=1139617375","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139617375?lang=en_us&edition=fundamental","pubTime":"2026-04-13 13:42","pubTimestamp":1776058937,"startTime":"0","endTime":"0","summary":"CUTIA-B (02487) rose more than 3% during trading. At the time of writing, the stock was up 3.25%, trading at HK$4.76, with a turnover of HK$409,900. The company announced the completion of its...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487","BK1161","BK4134","III","BK4585","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627886324","title":"Cutia Therapeutics completes China Phase III trial of CU-20101 for glabellar lines","url":"https://stock-news.laohu8.com/highlight/detail?id=2627886324","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627886324?lang=en_us&edition=fundamental","pubTime":"2026-04-13 10:12","pubTimestamp":1776046370,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics completed a Phase III trial in China for CU-20101, a botulinum toxin type A injection for moderate to severe glabellar lines.Topline results were already presented, with subject completion in November 2025 and database lock in January 2026.Study met key efficacy goals, showing CU-20101 performed comparably to BOTOX in improving frown lines.Safety profile was favorable, with no treatment-related serious adverse events and no new safety signals.Cutia highlighted a manufacturing approach that avoids animal-derived materials and human serum albumin, supporting product differentiation in aesthetics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cutia Therapeutics published the original content used to generate this news ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDLbJnWwJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627100785","title":"Cutia Therapeutics Completes Phase 3 Trial for Botulinum Toxin Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2627100785","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627100785?lang=en_us&edition=fundamental","pubTime":"2026-04-13 09:52","pubTimestamp":1776045157,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics  said it completed a Phase 3 clinical trial in China for its botulinum toxin type A product for treating moderate to severe glabellar lines, according to a Monday Hong Kong bourse filing.The study met primary and secondary endpoints, with efficacy comparable to Botox and a favorable safety profile.The pharmaceutical company said no treatment-related serious adverse events or new safety signals were observed.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK1161","02487","LENZ","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627010724","title":"BRIEF-Cutia Therapeutics Says Completion Of Phase III Clinical Trial Of Cu-20101","url":"https://stock-news.laohu8.com/highlight/detail?id=2627010724","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627010724?lang=en_us&edition=fundamental","pubTime":"2026-04-13 09:24","pubTimestamp":1776043447,"startTime":"0","endTime":"0","summary":"BRIEF-Cutia Therapeutics Says Completion Of Phase III Clinical Trial Of Cu-20101April 13 (Reuters) - Cutia Therapeutics 2487.HK:COMPLETION OF PHASE III CLINICAL TRIAL OF CU-20101Further company coverage: 2487.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nFWN40U08U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162875392","title":"CUTIA-B Completes Phase III Trial in China for Botulinum Toxin Type A Injection Targeting Glabellar Lines","url":"https://stock-news.laohu8.com/highlight/detail?id=1162875392","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162875392?lang=en_us&edition=fundamental","pubTime":"2026-04-13 08:22","pubTimestamp":1776039749,"startTime":"0","endTime":"0","summary":"CUTIA-B (02487) has announced the completion of its Phase III clinical trial in China for CU-20101 (Botulinum Toxin Type A for Injection), aimed at improving moderate to severe glabellar lines. The...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487","III","BK1161","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627104741","title":"Cutia Therapeutics -  Completion of Phase Iii Clinical Trial of Cu-20101","url":"https://stock-news.laohu8.com/highlight/detail?id=2627104741","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627104741?lang=en_us&edition=fundamental","pubTime":"2026-04-13 08:08","pubTimestamp":1776038910,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nFWN40U08U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02487","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195016335","title":"Cutia Therapeutics Reports Stable Share Capital in March; Confirms Public-Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1195016335","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195016335?lang=en_us&edition=fundamental","pubTime":"2026-04-02 21:02","pubTimestamp":1775134970,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics (CUTIA-B, HKEX: 02487) filed its Monthly Return for the period ended 31 March 2026, indicating no changes in authorised, issued or treasury share balances during the month....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622071940","title":"Cutia Therapeutics (SEHK:2487) Margins Stay Deep In The Red Challenging Profitability Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2622071940","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622071940?lang=en_us&edition=fundamental","pubTime":"2026-03-26 03:12","pubTimestamp":1774465953,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics (SEHK:2487) opened FY 2025 with first half revenue of C¥66.3 million and a basic EPS loss of C¥0.75, while trailing twelve month revenue sat at C¥336.2 million against a basic EPS loss of C¥1.03. The company reported revenue of C¥95.6 million in the first half of 2024, C¥184.0 million in the second half of 2024, and C¥66.3 million in the first half of 2025, with basic EPS losses of C¥0.66, C¥0.75 and C¥0.75 over those same periods. This sequence highlights that investors...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2487/cutia-therapeutics-shares/news/cutia-therapeutics-sehk2487-margins-stay-deep-in-the-red-cha","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2487/cutia-therapeutics-shares/news/cutia-therapeutics-sehk2487-margins-stay-deep-in-the-red-cha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LENZ","BK4139","BK4007","BK4539","02487","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168828574","title":"CUTIA-B Reports Annual Results: Shareholder Loss Narrows by 21.58% to RMB 340 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1168828574","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168828574?lang=en_us&edition=fundamental","pubTime":"2026-03-24 16:38","pubTimestamp":1774341515,"startTime":"0","endTime":"0","summary":"CUTIA-B (02487) announced its annual results for the period ending December 31, 2025. The group recorded revenue of RMB 336 million, an increase of 20.22% year-on-year. The loss attributable to...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621520870","title":"Cutia Therapeutics launches CU-40102 and CU-10201, reporting CNY 336 million in 2025 revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2621520870","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621520870?lang=en_us&edition=fundamental","pubTime":"2026-03-24 16:31","pubTimestamp":1774341101,"startTime":"0","endTime":"0","summary":"Cutia said its two main products, CU-40102 and CU-10201, began commercialization in late October 2025, adding new revenue streams in the company’s dermatology-focused portfolio.The company reported combined revenue of more than CNY 100 million from the two products following the launch.Cutia positioned the launches as expanding its reach across hospital, retail, and e-commerce channels, which could support broader market penetration in China’s dermatology treatment and care market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cutia Therapeutics published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 24, 2026, and is solely responsible","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL2MD0Xk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621520320","title":"Cutia Therapeutics FY2025 loss narrows 21.6% to RMB340 million on revenue up 20.2% to RMB336 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621520320","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621520320?lang=en_us&edition=fundamental","pubTime":"2026-03-24 16:31","pubTimestamp":1774341098,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics published an annual results announcement for the year ended Dec. 31, 2025.Revenue rose 20.2% to RMB336.2 million, while gross profit increased 36.5% to RMB195.8 million.Gross profit margin was 58%, up 7 percentage points, reflecting a higher sales contribution from high-margin product categories and cost control initiatives.Loss narrowed 21.6% to RMB340.2 million, after selling and distribution expenses fell 17.2% to RMB218.4 million on lower marketing expenses tied to improved traffic conversion efficiency and disciplined ROI management.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cutia Therapeutics published the original content used to generate this news brief via IIS, the Issuer Information Service operated by","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL2rg5pn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621793052","title":"Cutia Therapeutics - FY Revenue RMB336 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2621793052","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621793052?lang=en_us&edition=fundamental","pubTime":"2026-03-24 16:31","pubTimestamp":1774341085,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40B14U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02487","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145439024","title":"Fidelity International Increases Stake in CUTIA-B by 1.79 Million Shares at HK$5.01 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1145439024","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145439024?lang=en_us&edition=fundamental","pubTime":"2026-03-17 08:20","pubTimestamp":1773706857,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on March 11, Fidelity International purchased an additional 1.79 million shares of CUTIA-B (02487) at a price of HK$5.01 per share. The...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YMM","BK4503","LU0048575426.USD","BK4022","BK4539","LU1023057109.AUD","BK4526","IE00B12V2V27.USD","IE00BYQNZ168.SGD","LU2247934214.USD","02487","LU0359202008.SGD","BK4548","IE00BYTNYN87.SGD","LU0455707207.USD","LU0261950470.USD","SG9999011746.SGD","LU0359201612.USD","LU0502904849.HKD","BK1161","LU0251143458.SGD","BK4232","LU0359201885.HKD","LU0456842615.SGD","LU0327786744.USD","LU0572944931.SGD","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152428737","title":"CUTIA-B Secures Implied Clinical Trial Approval from China's NMPA for Topical Dutasteride Formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1152428737","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152428737?lang=en_us&edition=fundamental","pubTime":"2026-03-16 08:34","pubTimestamp":1773621282,"startTime":"0","endTime":"0","summary":"CUTIA-B (02487) announced that its Investigational New Drug application for CU-40104, a topical dutasteride formulation, has received implied clinical trial approval from China's National Medical...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02487"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":46,"code":"91000000","status":"200"}]}}